Ainos, Inc.: Ainos and Merdury Sign MoU to Explore Phase 3 Study of VELDONA Drug Candidate for Treatment of Oral Warts in HIV-Seropositive Patients
Ainos advances commercialization of its VELDONA® low-dose interferon treatment through strategic partnershipsSAN DIEGO, CA / ACCESSWIRE / March 14, 2023 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos"